Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Wörwag Pharma GmbH & Co. Kg is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This case is being reviewed by 1 distinct examiner in 1 distinct art unit. The presence of only one active matter suggests a targeted approach to its current intellectual property development in the Biotechnology & Pharmaceuticals sector.
The busiest examiner, CHANDRAKUMAR, NIZAL S, is assigned 1 pending office action. This single action accounts for all of the company's pending office actions. With only 1 distinct art unit involved, the prosecution is concentrated within a single administrative group. Practitioners should tailor their responses to the specific preferences of CHANDRAKUMAR, NIZAL S to achieve success in this Biotechnology & Pharmaceuticals matter.
Because the busiest examiner, CHANDRAKUMAR, NIZAL S, handles the 1 pending office action, there is no variety in examiner perspectives to navigate within the portfolio. The presence of 1 distinct examiner and 1 distinct art unit means that the company's prosecution strategy can be highly specialized. Practitioners must ensure that all arguments are tailored to the specific standards of this art unit and the individual expectations of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030740 | BIOFACTORS FOR THE TREATMENT AND PROPHYLAXIS OF DEMENTIA | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030740 | BIOFACTORS FOR THE TREATMENT AND PROPHYLAXIS OF DEMENTIA | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Non-Final OA | — | Pending | Oct 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWörwag Pharma GmbH & Co. Kg has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Wörwag Pharma GmbH & Co. Kg's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
